Brief: Argenx Announces Positive Topline Results From Phase 2 Study Of Fb102 In Celiac Disease
08/10/2026 06:01
BRIEF-Argenx Announces Positive Topline Results From Phase 2 Study Of Fb102 In Celiac Disease Oct 8 (Reuters) - argenx SE ARGX.BR:
ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF FB102 IN CELIAC DISEASE
STUDY MET PRIMARY ENDPOINT OF CHANGE FROM BASELINE IN RATIO OF VH:CD
FIRST PHASE 2 EVIDENCE THAT BLOCKING CD122 CAN PREVENT GLUTEN-INDUCED INTESTINAL DAMAGE IN PEOPLE LIVING WITH CELIAC DISEASE
ARGENX PLANS TO ADVANCE FB102 INTO PHASE 3 DEVELOPMENT OCTOBER 8, 2026
Source text: ID:nGNEbmgLdY
Further company coverage: ARGX.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;;))